Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Clinical treatment programs	$ 150	$ 213	$ 161
Total Revenues	150	213	161
Costs and Expenses:
Production/cost of goods sold	1,234	1,989	1,043
Research and development	8,360	9,508	6,722
General and administrative	7,723	9,056	6,691
Total Costs and Expenses	17,317	20,553	14,456
Operating loss	(17,167)	(20,340)	(14,295)
Interest and other income	791	1,606	624
Impairment loss	(800)	(9)	0
Interest expense	(16)	(24)	(41)
Gain from sale of income tax operating losses	686	1,328	2,272
Redeemable warrants valuation adjustment	281	85	2,425
Net loss	(16,225)	(17,354)	(9,015)
Other Comprehensive Income (Loss)
Unrealized gain (loss) on securities	(871)	331	(311)
Other than Temporary Impairment Losses, Investments, Portion in Other Comprehensive Loss, Net of Tax, Portion Attributable to Parent	800	9	0
Less: Premium amortization and realized losses	0	6	896
Net comprehensive loss	$ (16,296)	$ (17,008)	$ (8,430)
Basic and diluted loss per share (in usd per share)	$ (0.10)	$ (0.12)	$ (0.07)
Weighted average shares outstanding basic and diluted (in shares)	167,325,584	141,016,935	135,432,395